Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03918278 · ClinicalTrials.gov registry record · Phase 1
A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Completed
- Registry status
- Phase 1
- Development phase
- 222
- Enrollment target
NCT03918278 is a Phase 1 study that has completed, run by Merck Sharp & Dohme. The registered enrollment target is 222 participants.
The verdict
NCT03918278, a Phase 1 study, has completed, sponsored by Merck Sharp & Dohme.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 222 participants
- Enrollment target
Study Summary
This is a 2 part study. Part 1 is a dose escalation to determine the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) dose of MK-0482 administered as monotherapy and in combination with pembrolizumab (MK-3475) in participants with advanced solid tumors for which there is no available therapy which may convey clinical benefit. Part 2 is expansion cohort to determine safety and tolerability of MK-0482 in combination with pembrolizumab with and without chemotherapy in participants with advanced tumor specific cohorts.
Interventions
- DRUG Paclitaxel
- DRUG Gemcitabine
- BIOLOGICAL pembrolizumab
- DRUG Nab-paclitaxel
- BIOLOGICAL MK-0482
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 222 participants |
| Start Date | 2019-06-19 |
| Est. Completion | 2025-06-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03918278
The ClinicalTrials.gov registry entry for NCT03918278 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 222 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Paclitaxel is the first listed.
NCT03918278 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03918278 about?
NCT03918278 is a clinical study titled "A Study of MK-0482 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-0482-001)". This is a 2 part study. Part 1 is a dose escalation to determine the safety and tolerability and to establish a preliminary recommended Phase 2 dose (RP2D) dose of MK-0482 administered as monotherapy and in combination with pembrolizumab (MK-3475) in participants with advanced solid tumors for which...
What is the current status of trial NCT03918278?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 222 participants. The study started on 2019-06-19. Estimated completion is 2025-06-09.
What interventions are being tested in trial NCT03918278?
The interventions under investigation include: Paclitaxel (DRUG), Gemcitabine (DRUG), pembrolizumab (BIOLOGICAL), Nab-paclitaxel (DRUG), MK-0482 (BIOLOGICAL).
Who is sponsoring clinical trial NCT03918278?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.